/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

VAXXINITY, INC. Share Price Today: Live Updates & Key Insights

VAXXINITY, INC. share price today is $0.1107, up -15.26%. The stock opened at $0.122 against the previous close of $0.1311, with an intraday high of $0.1243 and low of $0.1093.

VAXXINITY, INC. Share Price Chart

style
pb-0

VAXXINITY, INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

VAXXINITY, INC. Share Price Performance

$0.1107 -0.1526(-15.26%) VAXX at 13 Mar 2026 03:43 PM Biotechnology
Lowest Today 0.1093
Highest Today 0.1243
Today’s Open 0.122
Prev. Close 0.1311
52 Week High 3.10
52 Week Low 0.10
Day’s Range: Low 0.1093 High 0.1243
52-Week Range: Low 0.10 High 3.10
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

VAXXINITY, INC. Institutional Holdings

Adage Capital Partners Gp LLC 2.37

BlackRock Inc 2.14

Vanguard Group Inc 1.89

Vanguard Total Stock Mkt Idx Inv 1.17

Prime Movers Lab LLC 0.95

iShares Russell 2000 ETF 0.78

Geode Capital Management, LLC 0.66

State Street Corporation 0.63

Vanguard Institutional Extnd Mkt Idx Tr 0.44

Fidelity Small Cap Index 0.31

Bank of America Corp 0.28

iShares Russell 2000 Growth ETF 0.28

Northern Trust Corp 0.26

State St Russell Sm/Mid Cp® Indx NL Cl C 0.26

Creative Planning Inc 0.22

Morgan Stanley - Brokerage Accounts 0.18

Bridgeway Capital Management, LLC 0.18

Bridgeway Ultra-Small Company Market 0.17

Fidelity Extended Market Index 0.17

Vanguard Russell 2000 ETF 0.12

State St Russell Sm Cap® Indx SL Cl I 0.12

Pathstone Family Office, LLC 0.12

Pathstone Holdings LLC 0.12

SCOGGIN LLC 0.12

NT R2000 Growth Index Fund - NL 0.10

NT R2000 Index Fund - NL 0.10

Bank of New York Mellon Corp 0.10

Charles Schwab Investment Management Inc 0.09

BlackRock Extended Mkt Composite 0.09

BlackRock Extended Equity Market K 0.08

Schwab Small Cap Index 0.08

NT R2000 Index Fund - DC - NL - 2 0.08

iShares Micro-Cap ETF 0.07

Northern Trust Russell 2000 Growth Index 0.07

NT R2000 Growth Index Fund - L 0.07

IEQ CAPITAL, LLC 0.07

BlackRock Russell 2500™ Index F 0.06

McAdam, LLC 0.06

Barclays PLC 0.05

Nuveen Asset Management, LLC 0.05

VAXXINITY, INC. Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

VAXXINITY, INC. Fundamentals

Market Cap 16.62 M

PB Ratio 4.5797

PE Ratio 0.0

Enterprise Value 1.15 M

Total Assets 44.35 M

Volume 3116115

VAXXINITY, INC. Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:66000 0.1M, FY20:557000 0.6M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:0 0.0M, FY21:-1871000 -1.9M, FY20:505000 0.5M, FY19:0 0.0M

Annual Net worth FY23:-65998000 -66.0M, FY22:-75210000 -75.2M, FY21:-138015000 -138.0M, FY20:-35377000 -35.4M, FY19:-14219000 -14.2M

Quarterly Revenue Q4/2023:0 0.0M, Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M, Q4/2022:0 0.0M

Quarterly Profit Q4/2023:-456000 -0.5M, Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M, Q4/2022:0 0.0M

Quarterly Net worth Q4/2023:-11392000 -11.4M, Q3/2023:-13145000 -13.1M, Q2/2023:-13977000 -14.0M, Q1/2023:-18409000 -18.4M, Q4/2022:-20472000 -20.5M

About VAXXINITY, INC. & investment objective

Company Information Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Organisation Biotechnology

Employees 57

Industry Biotechnology

CEO Ms. Mei Mei Hu J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow